

References

I-165

1. Preferred Drug List (PDL) Prior Authorization Criteria. North Dakota Department of Human Services. Medical Services Division. <http://www.hidesigns.com/ndmedicaid/pdl/>
2. Wilcox MH, Gering DN, Poxton IR, et al. Bezlotoxumab for prevention of recurrent clostridium difficile infection. *N Engl J Med.* 2017;305-17.
3. Prabhu VS, Comely OA, Golan Y, et al. Thirty-day readmissions in hospitalized patients who received bezlotoxumab with antibacterial treatment for Clostridium difficile infection. *Clin Infect Dis.* 2017;65(7):1218-1221.
4. Escudero-Sanchez R, Ruiz-RuizGomez M, Fernandez-Fradejas J, et al. Realworld experience with bezlotoxumab for prevention of recurrence of clostridioides difficile infection. *J Clin Med.* 2020;10(1):2.
5. Johnson S, Lavergne V, Skinner A, et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Updated Guidelines on Management of Clostridioides difficile Infection in Adults. *Clin Infect Dis.* 2021;73(5):1029-1044.
6. Bezlotoxumab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated July 1, 2019.
7. Clinical Pharmacology™ 2022. Tampa FL: Gold Standard, Inc. Bezlotoxumab.
8. Micromedex DrugDex Compendium®. 2022. Bezlotoxumab.
9. Zinplava™ (bezlotoxumab) injection, for intravenous use [package insert]. Merck Sharp & Dohme Corp. Whitehouse Station, NJ. Revised 10/2016.